BLU [NASD]
BELLUS Health Inc.
Index- P/E- EPS (ttm)-0.83 Insider Own3.30% Shs Outstand106.49M Perf Week26.04%
Market Cap1.04B Forward P/E- EPS next Y-0.73 Insider Trans0.00% Shs Float86.63M Perf Month21.01%
Income-69.80M PEG- EPS next Q-0.17 Inst Own88.54% Short Float13.24% Perf Quarter52.05%
Sales0.02M P/S65248.99 EPS this Y-66.90% Inst Trans-0.01% Short Ratio13.22 Perf Half Y31.15%
Book/sh2.63 P/B3.81 EPS next Y-39.20% ROA-33.00% Target Price14.03 Perf Year215.09%
Cash/sh2.25 P/C4.46 EPS next 5Y- ROE-35.60% 52W Range2.60 - 10.05 Perf YTD24.47%
Dividend- P/FCF- EPS past 5Y-46.50% ROI- 52W High-0.34% Beta0.20
Dividend %- Quick Ratio15.30 Sales past 5Y- Gross Margin- 52W Low285.38% ATR0.63
Employees40 Current Ratio15.30 Sales Q/Q0.00% Oper. Margin- RSI (14)70.29 Volatility9.09% 7.82%
OptionableYes Debt/Eq0.00 EPS Q/Q33.00% Profit Margin- Rel Volume1.40 Prev Close9.38
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume867.72K Price10.02
Recom1.80 SMA2022.22% SMA5022.73% SMA20043.58% Volume1,214,724 Change6.82%
Jul-29-21Initiated BTIG Research Buy $9
Jan-29-21Initiated RBC Capital Mkts Outperform $8
Nov-18-20Initiated Evercore ISI Outperform $12
Jul-07-20Downgrade Guggenheim Buy → Neutral
Jun-26-20Initiated H.C. Wainwright Buy $28
Sep-30-19Initiated Jefferies Buy $20
Sep-30-19Initiated Guggenheim Buy $12
Sep-30-19Initiated Cowen Outperform
Jun-13-22 06:13AM  
Jun-10-22 11:57AM  
Jun-09-22 08:25AM  
Jun-07-22 09:40AM  
Jun-01-22 07:00AM  
May-30-22 02:17PM  
May-25-22 08:35AM  
May-18-22 09:40AM  
May-11-22 04:50PM  
May-02-22 07:00AM  
Apr-25-22 04:01PM  
09:40AM  
Apr-07-22 08:23AM  
Apr-06-22 07:47AM  
Apr-04-22 10:40AM  
Mar-30-22 02:32PM  
Mar-24-22 04:51PM  
Mar-01-22 07:00AM  
Feb-23-22 09:00PM  
04:01PM  
Feb-16-22 12:00PM  
Dec-21-21 07:54AM  
Dec-17-21 09:30AM  
Dec-14-21 09:25PM  
05:19PM  
Dec-13-21 04:01PM  
11:19AM  
10:55AM  
10:18AM  
10:08AM  
09:40AM  
07:00AM  
05:31AM  
Nov-26-21 09:04AM  
Nov-10-21 06:05PM  
04:30PM  
07:00AM  
Nov-01-21 07:00AM  
Sep-24-21 09:42AM  
Sep-23-21 07:00AM  
Sep-15-21 10:32AM  
Sep-14-21 02:49PM  
12:27PM  
12:04PM  
Sep-13-21 11:02AM  
07:45AM  
Sep-12-21 08:09AM  
Sep-02-21 07:00AM  
Aug-23-21 07:00AM  
Aug-11-21 04:30PM  
Jul-14-21 02:41AM  
May-25-21 09:04AM  
07:00AM  
May-18-21 09:10AM  
May-17-21 11:15AM  
10:22AM  
09:07AM  
01:10AM  
May-16-21 03:21PM  
02:30PM  
10:00AM  
May-15-21 09:36PM  
12:44PM  
10:25AM  
05:03AM  
May-14-21 04:49PM  
03:20PM  
03:15PM  
02:20PM  
01:39PM  
12:10PM  
11:00AM  
10:41AM  
05:49AM  
May-13-21 10:00PM  
04:00PM  
03:20PM  
01:55PM  
01:00PM  
11:45AM  
11:00AM  
10:44AM  
06:15AM  
05:00AM  
May-12-21 07:51PM  
04:50PM  
03:20PM  
02:48PM  
01:15PM  
11:10AM  
11:00AM  
10:00AM  
09:00AM  
07:20AM  
07:00AM  
06:10AM  
May-11-21 06:34PM  
01:20PM  
12:30PM  
11:40AM  
BELLUS Health Inc., a clinical stage biopharmaceutical company, develops therapeutics for the treatment of refractory chronic cough (RCC) and other cough hypersensitivity indications. Its lead product candidate includes BLU-5937, an antagonist of the P2X3 receptor, which is in Phase II clinical trial for treatment of RCC and chronic pruritus. The company was incorporated in 1993 and is based in Laval, Canada.